Hepatitis C

Investigators found 31% of patients treated with aldafermin 0.3 mg had an improvement in liver fibrosis of at least 1 stage with no worsening of NASH.

Alcohol use was additionally associated with worse fibrosis, but no interaction was noted between the two risk factors.

HCV genotype 4 non-a/d subtypes are common in sub-Saharan Africa.

Resmetirom is being studied as a potential treatment for both NAFLD and NASH.

As the number of entecavir manufacturers increased from 1-11, the NADAC decreased from $30.12 to $1.93 per 0.5 mg tablet.

There are several barriers that prevent better HCV care, including availability and access to diagnostic and monitoring tests and the requirement for frequent medical visits during treatment.

Exposure to long-term prescription opioid therapy was linked to a 3.2-fold higher risk of HCV seroconversion compared to individuals who were prescription opioid-naïve or acute.

Weight loss could be beneficial for NASH and NAFLD patients.

TARGET-NASH as now expanded into European centers.

The US recommended HBV vaccines to be part of the infant immunization plan in 1991.

The rigidity of hospital settings and a lack of awareness prevents better hepatitis C virus diagnoses in the homeless population.

The recombinant vaccine resulted in higher rates of seroprotection in all subjects, particularly those 45 years and older.

Only 5 individuals of 195 who received liver transplantation had HCC reoccur more than 3 years following surgery.

Various factors decreased the likelihood of achieving SVR, including male gender, cirrhosis, recent injecting drug use, and previous DAA treatment.

There was a significant risk-adjusted trend toward decreasing inpatient mortality from 8.7% in 2010 to 7.4% in 2018 for readmissions within 30 days.

Volume of waiting list registrations and DDLTs for alcoholic hepatitis exceeded expected trends by a mean of 59.5% in waiting list registrations and 62.0% in DDLTs

This patient group had higher odds of death and longer lengths of hospital stays.

There was a higher risk of type 2 diabetes in patients with fibrosis stage F4 compared to patients with stage F0 or F2.

The 4 factors included baseline body mass index, fibrosis-4 index, albumin level at SVR, and alpha-foetoprotein level at SVR.

The most severe outcomes occurred in patients with a history of unhealthy alcohol use.

Risky sexual behavior is the sole independent predictor of acute HDV.

Incarceration history and current opioid agonist treatment was associated with antibody testing.

Only 1 patient died due to HCV-related complications following liver transplantation.

The accuracy of transient elastography following a sustained virologic response was considered poor.

The machine learning model outperformed a comparison logistic regression model in identifying high-risk patients for HBV.